In this episode of PsyFi, we sit down with Dr Stuart Seidman, a clinical psychologist treating patients on the severe end of mental health disorders. He believes psychedelic medicines are a game-changer for the field of psychology. PsyFi - Unraveling the Mysteries of Psychedelic Science WATCH the live recording: https://youtu.be/nataU-PaWuI Stuart Seidman | Partner, Negev Capital Stuart Seidman has a medical practice in psychopharmacology in New York City, owns an outpatient psychiatry clinic on the Upper West Side, and teaches psychiatry at the Chaim Sheba Medical Center in Israel. He went to medical school at Emory University, did a medical internship at the University of Pennsylvania, and was trained in epidemiology for 2 years at the Centers for Disease Control. He then completed a residency in psychiatry and a fellowship in psychopharmacology at Columbia University. He remained at Columbia as an attending physician for 15 years, during which his research focus was on the role of androgens in CNS function. He has been principal investigator of numerous clinical trials concerning exogenous testosterone and mood. Negev Capital Negev Capital is a psychedelic medical intervention investment fund with assets of USD$20+ million. We invest in drug discovery, with a focus on preclinical and/or Phase 1 stages of development. We aim to support those early stage companies in need of capital that promote the thoughtful, responsible, medical use of psychedelic medication for psychiatric disorders, and who have excellent management and science teams, and solid IP. We believe that psychedelic medications will be not only disruptive to the practice of psychiatry, but hold the potential to reduce enormous amounts of human suffering, and we are committed to helping the field mature, and further promote ways for these treatments to reach all of those in need.